Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C treatment at three Norwegian hospitals 2000-2011.
Isaksen K, Aabakken L, Grimstad T, Karlsen L, Sandvei PK, Dalgard O. Isaksen K, et al. Among authors: dalgard o. Tidsskr Nor Laegeforen. 2015 Dec 1;135(22):2052-8. doi: 10.4045/tidsskr.14.1478. eCollection 2015 Dec 1. Tidsskr Nor Laegeforen. 2015. PMID: 26627293 Free article. English, Norwegian.
[Treatment of chronic hepatitis C].
Bell H, Dalgard O, Bjøro K, Hellum KB, Myrvang B. Bell H, et al. Among authors: dalgard o. Tidsskr Nor Laegeforen. 2002 Apr 10;122(9):926-8. Tidsskr Nor Laegeforen. 2002. PMID: 12082838 Free article. Norwegian. No abstract available.
[Hepatitis C--a health problem also in Norway].
Vik IS, Skaug K, Dalgard O, Steen TW, Hoddevik G. Vik IS, et al. Among authors: dalgard o. Tidsskr Nor Laegeforen. 2008 Feb 28;128(5):563-6. Tidsskr Nor Laegeforen. 2008. PMID: 18311199 Free article. Review. Norwegian.
[Risk factors for hepatitis C among injecting drug users in Oslo].
Dalgard O, Egeland A, Ervik R, Vilimas K, Skaug K, Steen TW. Dalgard O, et al. Tidsskr Nor Laegeforen. 2009 Jan 15;129(2):101-4. doi: 10.4045/tidsskr.09.35002. Tidsskr Nor Laegeforen. 2009. PMID: 19151801 Free article. Norwegian.
Hepatitis C reinfection after sustained virological response.
Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O. Midgard H, et al. Among authors: dalgard o. J Hepatol. 2016 May;64(5):1020-1026. doi: 10.1016/j.jhep.2016.01.001. Epub 2016 Jan 11. J Hepatol. 2016. PMID: 26780289 Clinical Trial.
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group. Midgard H, et al. Among authors: dalgard o. Int J Drug Policy. 2017 Sep;47:230-238. doi: 10.1016/j.drugpo.2017.05.040. Epub 2017 Jun 19. Int J Drug Policy. 2017. PMID: 28633998 Clinical Trial.
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, Färkkilâ M, Balslev U, Belard E, Øvrehus A, Skalshøi Kjær M, Krarup H, Thorup Røge B, Hallager S, Madsen LG, Lund Laursen A, Lagging M, Weis N. Dalgard O, et al. PLoS One. 2017 Jul 13;12(7):e0179764. doi: 10.1371/journal.pone.0179764. eCollection 2017. PLoS One. 2017. PMID: 28704381 Free PMC article.
201 results